Emergent BioSolutions wins Canada NARCAN supply deal through 2029

Emergent BioSolutions Inc. (NYSE: EBS) has been awarded a standing offer by the Government of Canada to supply NARCAN® Nasal Spray, following a competitive procurement process, according to a company press release.

The agreement runs from October 1, 2026, through September 30, 2029, with an option to extend for two additional years. It replaces an existing five-year standing offer set to expire in September 2026.

Under the arrangement, authorized federal departments, agencies, Crown corporations, provinces, territories, and other designated public sector organizations across Canada may purchase NARCAN® Nasal Spray through individual call-ups.

NARCAN® Nasal Spray is a 4 mg intranasal naloxone spray indicated for emergency use to reverse known or suspected opioid overdose. The company states it is the only such product in Canada at that dosage with a four-year shelf life.

"Canada continues to face a significant public health challenge from the opioid crisis and expanding access to naloxone remains a critical component of overdose response efforts," said Paul Williams, head of products business, global government and public affairs at Emergent.

You May Also Be Interested In

• Google and Blackstone data-center venture hits delays at key sites - Bloomberg
• Legacy Gold names interim CFO after Andrew Dunlop resigns
• Medicure presents Phase 3 PNPO study data at European Epilepsy Congress